Literature DB >> 16136513

Immunohistochemical and microscopic studies on giant cells in tuberous sclerosis.

J Jozwiak1, S Jozwiak, P Skopinski.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant disease, caused by mutations in TSC1 or TSC2 genes, encoding hamartin and tuberin, respectively. The clinical picture of the disease is connected with the formation of hamartomas, mainly in the heart, kidneys and the brain. In three types of brain lesions: cortical tubers, subependymal nodules and subependymal giant-cell astrocytoma (SEGA) characteristic, so-called "giant cells" are found. In the present review we summarise immunohistochemical findings of two types of studies performed on giant cells aiming at establishing the expression of hamartin and tuberin level and determining the presence of neuron- or astrocyte-specific markers. Moreover, we support our argument with the summary of ultrastructural research done with the purpose of demonstrating structures characteristic of neural and/or glial cells. We conclude that giant cells in cortical tubers and SEGAs are the same undifferentiated cells that, depending on individual determination, can show neural or glial features.

Entities:  

Mesh:

Year:  2005        PMID: 16136513     DOI: 10.14670/HH-20.1321

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

Authors:  Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson
Journal:  Nat Genet       Date:  2012-06-24       Impact factor: 38.330

Review 2.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Authors:  John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

3.  Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update.

Authors:  Cynthia J Campen; Brenda E Porter
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

Review 4.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

5.  The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development.

Authors:  Magdalena Karbowniczek; Diana Zitserman; Damir Khabibullin; Tiffiney Hartman; Jane Yu; Tasha Morrison; Emmanuelle Nicolas; Rachel Squillace; Fabrice Roegiers; Elizabeth Petri Henske
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

6.  CD99: A potential Diagnostic Marker for Differentiating Sub-ependymal Giant Cell Astrocytoma From Other Mimickers: A Report of Five Cases.

Authors:  Alireza Sadeghipour; Navid Abdi; Pegah Babaheidarian
Journal:  Iran J Pathol       Date:  2017-07-01

7.  Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.

Authors:  Pike-See Cheah; Shilpa Prabhakar; David Yellen; Roberta L Beauchamp; Xuan Zhang; Shingo Kasamatsu; Roderick T Bronson; Elizabeth A Thiele; David J Kwiatkowski; Anat Stemmer-Rachamimov; Bence György; King-Hwa Ling; Masao Kaneki; Bakhos A Tannous; Vijaya Ramesh; Casey A Maguire; Xandra O Breakefield
Journal:  Sci Adv       Date:  2021-01-08       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.